People | June 03, 2022
Sanofi India appoints Preeti Futnani as GM, Vaccines
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Narayanan to lead SeQuent through next phase of consolidation and growth
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
Subscribe To Our Newsletter & Stay Updated
